hims & hers fda warning letter compounded semaglutide 2025 and warns investors about potential liability for FDA-regulated prescription drug ads – Partnership for Safe Medicines Hims & Hers stock crashes

doi: 10.1136/bmj.g2366 59 WentenMGaeblerJAHusseinMPelletierEMSmithDBGirasePet al

Shapsis Why Some Patients Cannot Tolerate GLP-1 Weight Loss Medications Many patients start medications such as Semaglutide or Tirzepatide to help with weight loss

Most providers transition patients to a higher concentration vial once they pass the 1.0 mg weekly dose

Each vial contains a combination of high-purity Retatrutide formulated under stringent quality control standards to ensure stability, precision, and consistency in controlled experimental research

As demand for these medications has soared in recent years, periodic shortages prompted companies like Hims & Hers to step into the market with compounded, sometimes cheaper options

November 2025: One of the physicians and researchers who investigated the link between Wegovy and vision loss is continuing his research on a link between the drug and condition